Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS.

Consistent with this, we observed a trend toward lower rates of severe (grade 3+) toxicities in the postchange group, although the difference did not reach statistical significance.

also in 111,027 other papers